<DOC>
	<DOCNO>NCT02005991</DOCNO>
	<brief_summary>This study see PF-05212377 , experimental drug treat symptom Alzheimer 's Disease , distribute brain one dose PF-05212377 administer orally healthy volunteer subject . The study also evaluate safety tolerability PF-05212377 subject measure level PF-05212377 blood .</brief_summary>
	<brief_title>A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377</brief_title>
	<detailed_description />
	<criteria>Males female must least 18 year age old 55 year age Body Mass Index ( BMI ) must 17.5 30.5 . Subjects must sign consent form comply schedule visit , treatment plan , lab test study procedure . Females must pregnant , breastfeed , able child . Subjects must severe acute chronic medical psychiatric condition history evidence blood , kidney , glandular , lung , stomach , intestine , heart , blood vessel , liver , psychiatric , nerve , allergic problem ( include drug allergy ) , except mild seasonal allergy . Subjects must drink alcohol excessively take illicit drug . Male subject use condoms prevent potential transfer drug semen partner begin dose study drug use highly effective method birth control partner ( ) childbearing potential 28 day last dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>PF-05212377</keyword>
	<keyword>phase 1</keyword>
	<keyword>open-label</keyword>
	<keyword>5-HT2a receptor occupancy</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>healthy subject</keyword>
	<keyword>brain</keyword>
	<keyword>cortex</keyword>
	<keyword>alzheimers disease</keyword>
</DOC>